Dr. Paramvir S. Sidhu, MD
Rheumatology (Rheumatology Physician)
13555 W Mcdowell Rd, Suite 209
Goodyear, AZ 85395
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 366
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AZ license 41707 -
Internal Medicine Physician
AZ license 78212
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
Medical groups
- Honorhealth Ambulatory (630 clinicians)
- Honorhealth Medical Group, LLC (332 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 366
- Services billed
- 1,130
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, romosozumab-aqqg, 1 mg | 5,040 | 14 |
| Injection, denosumab, 1 mg | 2,700 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 428 | 245 |
| Injection of drug or substance under skin or into muscle | 72 | 59 |
| Established patient office or other outpatient visit, 20-29 minutes | 49 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 39 | 39 |
| Dxa bone density measurement of hip, pelvis, spine | 36 | 36 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Goodyear, AZ | 151 |
| Leflunomide Other prescribers in Goodyear, AZ | 71 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Goodyear, AZ | 60 |
| Rinvoq (upadacitinib) | 52 |
| Allopurinol Other prescribers in Goodyear, AZ | 44 |
| Prednisone Other prescribers in Goodyear, AZ | 43 |
| Diclofenac Sodium Other prescribers in Goodyear, AZ | 41 |
| Hydroxychloroquine Sulfate Other prescribers in Goodyear, AZ | 41 |
| Kevzara (sarilumab) | 34 |
| Alendronate Sodium Other prescribers in Goodyear, AZ | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $772,413 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Amgen Inc. - A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Amgen Inc. - A phase 2/3, randomized, double-blind, placebo-controlled, parallel-gr
GlaxoSmithKline, LLC. - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB SA · Completed · NCT06624228 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.